Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography

Indian Journal of Nuclear Medicine

Volumn 28, Issue 3, 2013, Pages 187-188

  Kamaleshwaran, Koramadai Karuppusamy ^a   Subramanian, Paul Vannan ^a   Natarajan, Sudhakar ^a   Mohanan, Vyshak ^a   Shinto, Ajit Sugunan ^a  

^a KOVAI MEDICAL CENTER AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYLENEDIAMINE N,N' DIACETIC ACID HYDRAZINONICOTINYL TYR3 OCTREOTIDE TECHNETIUM TC99M; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CASE REPORT; CLINICAL FEATURE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; LETTER; MALE; NEUROENDOCRINE TUMOR; PELVIS RADIOGRAPHY; RADIATION DOSE; RADIOISOTOPE DIAGNOSIS; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84885973605     PISSN: 09723919     EISSN: 09740244     Source Type: Journal    
DOI: 10.4103/0972-3919.119520     Document Type: Letter

References (7)

1. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
2. Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: A new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318-25.
3. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, et al. Image fusion analysis of (99m) Tc-HYNIC-Tyr (3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 2005;32:1440-51.
4. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
5. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41:1114-9.
6. Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008;113:1056-67.
7. Guggenberg EV, Mikolajczak R, Janota B, Riccabona G, Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci 2004;93:2497-506.